文献速递糖尿病骨质疏松与钙磷/甲状旁腺

糖尿病、骨骼与降糖药物:临床结局

Diabetes, bone and glucose-lowering agents: clinical outcomes.
PubMed 文献 · Diabetologia · 2017-04-27

本文综述糖尿病、骨骼与降糖药物的关系,重点讨论糖尿病患者骨折风险评估的挑战。文章指出骨密度T值和骨折风险评估工具(FRAX)在糖尿病患者中倾向于低估风险,糖尿病病程、并发症和血糖控制不佳是骨折风险增加的临床标志,并讨论降糖药物对骨折风险的潜在影响及老年糖尿病患者骨折预防的现状。

要点

  • 骨密度T值和FRAX在糖尿病患者中倾向于低估骨折风险。
  • 糖尿病病程、并发症和血糖控制不佳是骨折风险增加的临床标志。
  • 噻唑烷二酮类对骨骼有负面作用,降糖药物可能独立于血糖控制影响骨折风险。

核心结论

  • 老年糖尿病患者骨折及骨折相关并发症风险较高,降低骨折风险是糖尿病管理的重要目标。
  • 临床医生应意识到骨密度T值和FRAX在糖尿病患者中倾向于低估骨折风险。
  • 糖尿病病程、并发症和血糖控制不佳是骨折风险增加的临床标志。

研究设计与样本

  • 本文为综述,讨论糖尿病、骨骼与降糖药物的关系,并涉及老年糖尿病患者骨折预防的当前认识。

主要发现

  • 骨密度T值和骨折风险评估工具(FRAX)在糖尿病患者中倾向于低估骨折风险。
  • 噻唑烷二酮类对骨骼具有负面作用。
  • 降糖药物可能独立于其血糖控制效果影响骨折风险。

临床怎么用

  • 标准风险评估工具可用于预测骨折,但临床医生需知晓其在糖尿病患者中低估风险的趋势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older adults with diabetes are at higher risk of fracture and of complications resulting from a fracture. Hence, fracture risk reduction is an important goal in diabetes management. This review is one of a pair discussing the relationship between diabetes, bone and glucose-lowering agents; an accompanying review is provided in this issue of Diabetologia by Beata Lecka-Czernik (DOI 10.1007/s00125-017-4269-4 ). Specifically, this review discusses the challenges of accurate fracture risk assessment in diabetes. Standard tools for risk assessment can be used to predict fracture but clinicians need to be aware of the tendency for the bone mineral density T-score and the fracture risk assessment tool (FRAX) to underestimate risk in those with diabetes. Diabetes duration, complications and poor glycaemic control are useful clinical markers of increased fracture risk. Glucose-lowering agents may also affect fracture risk, independent of their effects on glycaemic control, as seen with the negative skeletal effects of the thiazolidinediones; in this review, the potential effects of glucose-lowering medications on fracture risk are discussed. Finally, the current understanding of effective fracture prevention in older adults with diabetes is reviewed.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Schwartz AV. Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia. 2017. PMID: 28451714. doi:10.1007/s00125-017-4283-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。